Effect of inactivated vaccine boosters against severe and critical COVID‐19 during the Omicron BA.5 wave: A retrospective analysis of hospitalized patients in China

Abstract Few real‐world analyses of the ability of vaccines to protect against severe COVID‐19 have been published. In this real‐world study, we compared the prevalence of severe or critical COVID‐19 between patients at our hospital who were not vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) or who had been vaccinated partial, full, or booster course with the CoronaVac, containing inactivated virus propagated in Vero cells. Data from electronic health records were retrospectively analyzed for 4090 inpatients with COVID‐19 who were treated at West China Hospital, Chengdu between December 6, 2022 and February 14, 2023. Clinicodemographic characteristics and COVID‐19 severity were compared among patients who had been vaccinated 0, 1, 2 or more times with inactivated vaccine CoronaVac. To evaluate vaccine effectiveness over time, we plotted Kaplan−Meier curves with the percentage of patients with the outcome of severe or critical COVID‐19 from the time of their last vaccine dose according to vaccination status. Ordinal logistic regression was used to assess associations between vaccination status and COVID‐19 severity. Cox regression was used to identify risk factors for severe or critical COVID‐19. Among the 4090 patients, 171 had been vaccinated partial and 423 twice with the full CoronaVac regimens, while 905 had been vaccinated three times (boosted). The prevalence of severe or critical COVID‐19 among patients was 11 percentage points lower among those vaccinated (40%) at least twice than among those unvaccinated (51%) ( p ＜ 0.001), while it was 10% points lower among those who had received a booster (41%) than among those unvaccinated (51%) ( p ＜ 0.001). Protection against severe or critical COVID‐19 due to vaccination was significantly weakened by being older than 65 years, being male, or having diabetes, chronic heart disease, autoimmune disease, or chronic lung disease. Completing a full course of immunization with inactivated vaccine CoronaVac against SARS‐CoV‐2 can reduce the risk of severe or critical COVID‐19 due to the Omicron BA.5 subvariant.